Open AccessThis article is
- freely available
Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?
Department of Clinical and Experimental Medicine, Infectious Medicine Faculty of Health Sciences, Linköping University, 581 83 Linköping, Sweden
The Åland Borrelia Group, Åland, 22100 Mariehamn, Åland, Finland
Department of Infectious Diseases, County Council of Östergötland, 581 85 Linköping, Sweden
Center for Clinical Research (CKF) Dalarna, 791 36 Falun, Sweden
Department of Clinical and Experimental Medicine, Clinical Immunology, Linköping University, S-581 83 Linköping, Sweden
Department of Clinical Immunology and Transfusion Medicine, County Council of Östergötland, 581 85 Linköping, Sweden
Department of Laboratory Medicine, NÄL, 461 85 Trollhättan, Sweden
* Author to whom correspondence should be addressed.
Received: 1 April 2012; in revised form: 7 May 2012 / Accepted: 8 May 2012 / Published: 8 June 2012
Abstract: The aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting. Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Åland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB). Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-γ-secreting cells were assayed by the ELISPOT test. The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36% and a specificity of 82%. The findings in this study show that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB.
Keywords: Borrelia burgdorferi; neuroborreliosis; ELISPOT; cerebrospinal fluid; diagnostic test; sensitivity; specificity
Citations to this Article
Cite This Article
MDPI and ACS Style
Nordberg, M.; Forsberg, P.; Nyman, D.; Skogman, B.H.; Nyberg, C.; Ernerudh, J.; Eliasson, I.; Ekerfelt, C. Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? Cells 2012, 1, 153-167.
Nordberg M, Forsberg P, Nyman D, Skogman BH, Nyberg C, Ernerudh J, Eliasson I, Ekerfelt C. Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? Cells. 2012; 1(2):153-167.
Nordberg, Marika; Forsberg, Pia; Nyman, Dag; Skogman, Barbro H.; Nyberg, Clara; Ernerudh, Jan; Eliasson, Ingvar; Ekerfelt, Christina. 2012. "Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?" Cells 1, no. 2: 153-167.